A systematic review and meta-analysis of ten controlled studies involving 304 participants found no lasting changes in cognition, creativity, emotional processing, or personality from serotonergic psychedelics for most measures. However, faster reaction times were observed for recognizing disgust and sadness in active treatment groups. The authors call for larger samples and standardized methods to confirm these preliminary findings.
A pilot study will test the safety and feasibility of combining subanaesthetic ketamine with cognitive behavioural therapy for adults with methamphetamine use disorder. Twenty participants seeking to reduce or stop methamphetamine use will receive three subcutaneous ketamine doses (0.75 to 0.9 mg/kg) at weekly intervals and four therapy sessions over four weeks. The study will measure recruitment time, eligibility rates, treatment completion, retention, and acceptability over eight weeks, and explore changes in methamphetamine use, cravings, withdrawal, quality of life, and treatment satisfaction over 24 weeks. No pharmacological treatments currently exist for this condition, and psychotherapy alone is only moderately effective.